Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 5/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | THPO | P40225 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6883241 | 1.00 | ADORA2A (0.54) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL28557481 | 0.82 | ADORA2A (0.55) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL1138979 | 0.81 | ADORA2A (0.60) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL18844803 | 0.81 | CYP2C19 (0.62) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL14929125 | 0.81 | CYP2C19 (0.62) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL18512921 | 0.81 | CYP2C19 (0.62) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL343478 | 0.81 | CYP2C19 (0.62) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL14931005 | 0.81 | CYP2C19 (0.62) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL62505 | 0.81 | CYP2C19 (0.62) | ADORA2AADORA2BADORA3ADORA1CYP2C19 | |
| SCHEMBL25101160 | 0.80 | CYP2C19 (0.61) | ADORA2AADORA2BADORA3ADORA1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040241706-A1 | Highly specific modulators of GTPases for target validation | IRM, LLC | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040241706-A1 | Highly specific modulators of GTPases for target validation | CDC42, ARHGDIB, ARHGEF2 | ADORA2A 4341/4885ADORA2B 4641/4885ADORA3 4635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.